v**********m
发帖数: 5516 | 1 重要的时间点和market 都能在这篇文章里找到。
================
http://www.investorideas.com/CO/BPAX/news/2011/07151.asp
Mr. Stephen M. Simes, President and CEO of BioSante Pharmaceuticals, Inc. (
NASDAQ: BPAX), Discusses the Potential of Future Partners or Acquisition
Point Roberts, WA, LINCOLNSHIRE, Ill – July 15, 2011 –(Investorideas.com
newswire.com) Investorideas.com, an investor research portal covering
leading sectors including biotech and pharma stocks, features an exclusive Q
&A interview with Mr. Stephen M... 阅读全帖 |
|
a*****h
发帖数: 484 | 2 再贡献一个今天出消息过一段时间可能n*的匹克,感觉有戏，YMYD
BPAX(2.25 +0.4701 (+26.41%))
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase
III ProgramFont size: A | A | A8:00 AM ET 8/13/09 | BusinessWire
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), today announced positive
safety data in its ongoing LibiGel Phase III clinical development program.
BioSante reported that with over 1,250 women enrolled and almost 825 women-
years of exposure in its LibiGel Phase III clinical development program,
the... 阅读全帖 |
|
v**********m
发帖数: 5516 | 3 马后炮，在我的个人小抄本里找到这篇文章
=============
On 11 May 2011, BioSante's share price closed at $2.33. But by 25 May, two
weeks later, it shot up to $2.92:
1. While the stock market began its May-June descent...
2. On the heels of reporting a huge loss in Q1...
3. And on no news.
Scouring the news including SEC filings, these events stand-out:
* 10 May BioSante reported "BioSante 1Q loss widens on costs". The
company reported losing $17.3M or 20 cents per share and zero revenue. Yet
other than a... 阅读全帖 |
|
p********e
发帖数: 1960 | 4 http://seekingalpha.com/article/287381-the-two-very-best-biotec
The market correction has been a gift.
After combing through low-flyer biotechs for over one year, I am convinced
that the two very best biotechs under $3/share are: BioSante Pharmaceuticals
(BPAX) and Antares Pharma (AIS). If I was pressed to add a third stock to
my list, it would be AEterna Zentares (AEZS), but for now I will stick with
only two. The basis for my researched conclusion is as follows:
BioSante
BioSante recently gave... 阅读全帖 |
|
f**********g
发帖数: 2252 | 5 Investors Hopeful for Blockbusters From BioSante and Sunesis
1 hours 15 minutes ago - Marketwire via Comtex
MarketwireRecent studies have shown that the chances of FDA approval for
early stage drugs is dropping significantly. Although it remains an exciting
time in the biotech sector with several potential blockbusters working
their way through the regulatory process, now, more than ever, many analysts
are urging investors to use caution. The Bedford Report examines the
outlook for companies in ... 阅读全帖 |
|
v**********m
发帖数: 5516 | 6 July 18, 2011 07:55 AM Eastern Daylight Time
BioSante Pharmaceuticals Announces Management Team Additions
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ:
BPAX), today announced the appointment of Sandra Croak-Brossman, MS, Ph.D.,
as Vice President, Regulatory Affairs and Quality Assurance, and Patricia M.
Adams, MS as Vice President, Human Resources. Dr. Croak-Brossman assumed
this new role effective today. Ms. Adams assumed her new role effective in
May 2011.
“W... 阅读全帖 |
|
d******8
发帖数: 1972 | 7 h前几天2.55买了一些，不知是好消息还是坏消息？今天的交易量比较大，下跌趋势，但和这几天大盘相比，还是很坚挺。
更新。
多亏安排顶光头的文章，看完后就一直盯着，感觉不对，跌破2.45.就应该卖了，犹豫一会就下到了2.2下，后来在2.17卖了。
ttp://www.thestreet.com/story/11345313/1/biosante-pharma-readying-release-of
-female-viagra-study-results.html
LINCOLNSHIRE, Ill. (TheStreet) --BioSante Pharmaceuticals(BPAX_) will tell
us soon whether or not its testosterone gel improves the sex lives of
certain women.
A scheduled presentation Wednesday by BioSante executives at an investor
conference was cancelled this mor... 阅读全帖 |
|
d******8
发帖数: 1972 | 8 BioSante Pharmaceuticals Announces Results from LibiGel® Efficacy Trials
LibiGel does not achieve primary endpoints in the treatment of hypoactive
sexual desire disorder in postmenopausal women |
|
f**********g
发帖数: 2252 | 9 来自主题: _pennystock版 - Bpax BioSante (BPAX) 发表LibiGel第三阶段临床实验数据为正面，独立数据监督委员会(
DMC)完成第9次的第三阶段临床实验的心血管事件与乳癌安全研究审查。DMC的建议是
LibiGel安全研究应该按照FDA协定内容继续进行。 |
|
S****X
发帖数: 2301 | 10
都9
没有吧？ 8月29有效性试验结束，一直都是schedule是12月公布结果哈。会安排在11月
NDA结果之后公布吧，万一药没批，libigel phase III 结果还能救救命。 而且,8月
12-20大量的inside buy， 因此估计至少1个半月到2月内， 不会有重要消息公布的。 |
|
t**u
发帖数: 1572 | 11 Interim result will be checked every 3 months according to seekingalpha news.
There was an interim in May, but the result was reported in June. So there
should be an interim in August. But I don't know when the result will be
disclosed. But there should be no worry about the interim safety results.
============
Why BioSante Expects a Positive Review of Drug for Female Sexual Disorder
by: Kaushik Paul
May 10, 2011 | about: BPAX
By May 2011, an independent Data Monitoring Committee (DMC) is expect... 阅读全帖 |
|
|
b*****h
发帖数: 783 | 13 Libigel trial 失败，大瀑布来了。 |
|
b*****h
发帖数: 783 | 14 BPAX 的LibiGel 出乎意料的失败让BPAX跌到了谷底，因为BPAX一直是主要开发性药，
这次失败，导致他的这个方向基本流产。
但是，BPAX 还有另一个方向 cancer vaccine.
2008年BPAX 以很便宜的价格收购了CEGE 的GVAX 技术，CEGE可能有些人还记得，是当
年和DNDN竞争prostate cancer cell therapy 领域的，而且一度被看好，因为他们的
治疗方式不象dndn那么针对每个人，治疗起来方便很多，理论上是多靶点免疫，强于
dndn的单靶点。但是GVAX的临床三期试验组在试验中期病人死亡变多而失败。
BPAX 已经重新开始GVAX 的一系列早期临床试验，这一部分相信以后会称为bpax的主要
业务。 |
|
